


<HTML>
<HEAD>
<TITLE>Individual.com</TITLE>
<META HTTP-EQUIV="Pragma" CONTENT="no-cache">
</HEAD>

<!-- eLogic.com publishing systems 8/18/00 Time-3:48:54 AM -->

















































<BODY BGCOLOR="#FFFFFF">

        <!-- BEGIN AD SPACE -->


                <TABLE BORDER="0" WIDTH="475" CELLSPACING="0" CELLPADDING="0">
                <TR>
                  <TD HEIGHT="100" VALIGN="MIDDLE">
		
										<!-- Begin DoubleClick ad head -->
										<NOLAYER>
										<IFRAME SRC="http://ad.doubleclick.net/adi/finance.individual.com/PNP_search_results;kw=;tickr=;!category=fin_comp;mode=display_news;u=;sz=468x60;ord=1209?" name="banner1" frameborder=0 marginheight=0 marginwidth=0 width=468 height=80 scrolling=no>
										<A HREF="http://ad.doubleclick.net/jump/finance.individual.com/PNP_search_results;kw=;tickr=;!category=fin_comp;mode=display_news;u=;sz=468x60;ord=1209?" target="_top"><IMG BORDER="0" SRC="http://ad.doubleclick.net/ad/finance.individual.com/PNP_search_results;kw=;tickr=;!category=fin_comp;mode=display_news;u=;sz=468x60;ord=1209?"><BR>Click Here!</A>
										</IFRAME>
										</NOLAYER>
										<ILAYER ID=banner1 VISIBILITY=HIDE HEIGHT=80 WIDTH=468></ILAYER>
										<!-- End DoubleClick ad head -->
									</TD>
                </TR>
                </TABLE>

        <!-- END AD SPACE -->




<table width=645 cellpadding=0 cellspacing=0 border=0>
<tr valign=top>
<td width=470>



<p>

<table width=470 cellpadding=0 cellspacing=0 border=0 bgcolor="#ffffff">
<tr valign=top>
<td>

<b><font face="Arial,Helvetica"  color="#345B8A">Teva Pharmaceutical Industries, Ltd. and Aventis Pharmaceuticals Announce Record 2Q 2000 Sales of Copaxone(R</b></font><br clear=all><table border="0" width="140" cellspacing="0" cellpadding="2" align=right><tr><td bgcolor="#345B8A"><table border="0" width="100%" cellspacing="0" cellpadding="0" bgcolor="#FFFFCC" align=right><tr BGCOLOR="#345B8A" align=right><td align=left><font size=-2 face="arial" color="ffffff">Ticker</font></td><td><font size=-2 face="arial" color="ffffff">Last</font></td><td colspan=2><font size=-2 face="arial" color="ffffff">Change</font></td></tr><tr align=right><td align=left><font size=-2 face="arial, geneva"><a href="quote.asp?ticker=AVE">AVE</a></font></td><td><font size=-2 face="arial">$78.25</font></td><td><font size=-2 face="arial">$-0.19</font></td><td><font size=-2 face="arial"><img src="images/arrow-down.gif"></font></td></tr><tr align=right><td align=left><font size=-2 face="arial, geneva"><a href="quote.asp?ticker=TEVA">TEVA</a></font></td><td><font size=-2 face="arial">$61.75</font></td><td><font size=-2 face="arial">$-1.31</font></td><td><font size=-2 face="arial"><img src="images/arrow-down.gif"></font></td></tr><tr><td colspan=4><font size=-2 face="arial">Quotes 20 min delay.</font></td></tr></TABLE></td></tr></TABLE><font><br>Monday July 31  5:00pm<br>Source: PR Newswire<br><p><P><B>

          - Partnership Builds on Success, Plans Aggressive Growth -
</B></P>
<P>
    JERUSALEM, and PARSIPPANY, N.J., July 31 /PRNewswire/ -- Teva
Pharmaceutical Industries, Ltd., (Nasdaq: <A HREF="stock_info.asp?ticker=TEVA">TEVA</A>) and Aventis Pharmaceuticals
today announced record North America in-market sales of COPAXONE(R)
(glatiramer acetate for infection) of $53 million in the 2nd quarter of 2000,
up 60% from the comparable quarter of 1999. Total in-market sales of Copaxone
were $59.4 million in the quarter.
</P>
<P><B>
    (Logo:  http://www.newscom.com/cgi-bin/prnh/20000501/NYM197 )
</B></P>
<P>
    In the U.S., the world's largest multiple sclerosis (MS) market, Copaxone,
for the reduction of relapses in relapsing-remitting multiple sclerosis
(RR-MS), continues to be the fastest growing MS drug therapy based on total
prescriptions* and the only one whose growth is outpacing the MS drug market
in percentage of new and total prescriptions.
</P>
<P>
    Early this year, Copaxone reached a major milestone when it overtook the
number two position in terms of total prescriptions in the three-drug multiple
sclerosis market.
</P>
<P>
    Teva Marion Partners (TMP) and TMP Canada are partnerships between Aventis
and Teva, which were formed to market Copaxone in North America.
</P>
<P>
    "We are extremely pleased to see growth in our market share as
neurologists gain more experience with Copaxone," said Larry Downey, president
and chief executive officer of TMP. "We are excited about our momentum going
forward as we look to bring additional data for Copaxone to the marketplace."
</P>
<P>
    Downey said the company anticipates continued strong growth based on
increasing acceptance of Copaxone and continuing innovative MS patient
outreach and education programs. Currently, TMP and Teva are conducting global
MS research totaling approximately $70 million that will extend over a
three-year period.
</P>
<P>
    The most common side effects reported in clinical trials of Copaxone were
injection-site reactions, vasodilatation, chest pain, asthenia, infection,
pain, nausea, arthralgia, anxiety, and hypertonia.
</P>
<P>
    Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the
top 50 pharmaceutical companies and among the largest generic pharmaceutical
companies in the world. Over 80% of its sales are outside Israel, mainly in
North America and Europe. The company develops, manufactures and markets
generic and branded pharmaceuticals and active pharmaceutical ingredients.
</P>
<P>
    Aventis Pharmaceuticals conducts the U.S. business of Aventis Pharma AG,
the pharmaceutical company of Aventis S.A. (NYSE: <A HREF="stock_info.asp?ticker=AVE">AVE</A>). Aventis
Pharmaceuticals is dedicated to treating and preventing human disease through
the discovery, development, manufacture and sale of innovative pharmaceutical
products aimed at satisfying unmet medical needs. Aventis Pharmaceuticals
focuses on important therapeutic areas such as cardiology, oncology,
infectious diseases, arthritis, allergies and respiratory disorders, diabetes,
and central nervous system disorders. The corporate headquarters for Aventis
Pharmaceuticals is in Parsippany, N.J.
</P>
<P>
    Aventis Pharma comprises Aventis Pharmaceuticals; Aventis Pasteur, a world
leader in vaccines, with corporate headquarters in Lyon, France; and Aventis
Behring, a world leader in therapeutic proteins, with corporate headquarters
in King of Prussia, Pa. The corporate headquarters of Aventis Pharma is in
Frankfurt, Germany.
</P>
<P>
    One of the world's leading life sciences companies, Aventis S.A. is
focused on two core business areas: pharmaceuticals and agriculture. With
global headquarters in Strasbourg, France, Aventis employs around 95,000
people in more than 120 countries. Aventis was created in December 1999 by the
combination of Hoechst AG and Rhone-Poulenc, S.A.
</P>
<UL>
<LI>   Based on IMS Weekly MS Market prescriptions Apr-June 2000 vs. Apr-June
1999.
</UL>
<P>
    Statements in this news release other than historical information are
forward-looking statements subject to risk and uncertainties. Actual results
could differ materially, depending on factors such as the availability of
resources, the timing and effects of regulatory actions, the strength of
competition, the outcome of litigation, and the effectiveness of patent
protection. Additional information regarding risks and uncertainties is set
forth in the current Annual Report on Form 20-F of Aventis and Teva on file
with, and in Aventis' and Teva's reports on Form 6-K furnished to, the
Securities and Exchange Commission.
</P>
<P>
    To receive a copy of this release or any recent release via fax, call
Aventis Pharmaceuticals' automated news fax line at 800-556-7422, or
816-966-3434. To receive prescribing information, call 800-887-8100, or visit
the Aventis Pharmaceuticals U.S. Web site at <A HREF="http://www.copaxone.com">http://www.copaxone.com</A>.
</P>
<TABLE>
<TR><TH VALIGN=TOP>Source:</TH><TD>Aventis Pharmaceuticals and Teva Pharmaceutical Industries, Ltd.
</TD></TR>
<TR><TH VALIGN=TOP>Contact:</TH><TD>Charles F. Rouse III of Aventis Pharmaceuticals, 973-394-6050;
or Dr. Aaron Schwartz of Teva Pharmaceutical Industries, Ltd.,
+011-972-5-030-4458
</TD></TR>
</TABLE>
<br></font>

</td>
</tr>
</table>





</TD>
<td width="25" align=right><img src="images/spacer.gif" width="25" height="1" border="0"></td>
<td align=right width="150"><!-- Begin DoubleClick ad head -->
<NOLAYER>
<IFRAME SRC="http://ad.doubleclick.net/adi/finance.individual.com/PNP_search_results_column;kw=;tickr=TEVA;!category=fin_comp;mode=display_news;u=;sz=150X500;ord=31209?" name="column1" frameborder=0 marginheight=0 marginwidth=0 width=150 height=500 scrolling=no>
<A HREF="http://ad.doubleclick.net/jump/finance.individual.com/PNP_search_results_column;kw=;tickr=TEVA;!category=fin_comp;mode=display_news;u=;sz=150x500;ord=31209?" target="_top"><IMG BORDER="0" SRC="http://ad.doubleclick.net/ad/finance.individual.com/PNP_search_results_column;kw=;tickr=TEVA;!category=fin_comp;mode=display_news;u=;sz=150X500;ord=31209?"><BR>Click Here!</A>
</IFRAME>
</NOLAYER>
<ILAYER ID=column1 VISIBILITY=HIDE HEIGHT=500 WIDTH=150></ILAYER>
<!-- End DoubleClick ad head --></td>
                        
                </TR>
                </TABLE>
                
<table border="0" cellspacing="0" cellpadding="0" width="470">
<TR>
<TD align="center">
<IMG SRC="images/73x29.gif" WIDTH="73" HEIGHT="29"><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-2">&nbsp;&nbsp;<A HREF="http://www.individual.com/terms.shtml" TARGET="CONTENT"><B>Copyright &copy; 2000</B></A>, <A HREF="http://www.individual.com/about.shtml" TARGET="_top"><B>Individual.com, Inc.</A></B><font size="-5"><sup><font color="#0000CC">TM</font></sup></font></TD>
</TR>

</table>                
                
 <!--               </TD>
        </TR>
        <! END FOOTER LINKS >

        <! RED SPACER ROWS - DO NOT ERASE > 

        </TABLE>
        <! End Footer Table >
        
        </TD>
</TR>
<! End Footer >
</table>-->
<P>
<table width=470 border=0>
	<tr valign="Top">
		<td align="center">

	<font size=1 face="MS Sans Serif" color="#000000">Copyright © 1997-2000, Technology by
	<a href="http://www.elogic.com/" target="_blank"><font size=1 face="MS Sans Serif" color="#000000"><u>eLogic Corporation</u></u></a> &nbsp;&nbsp;All Rights Reserved. 

	<font size=1 face="MS Sans Serif" color="#000000"><P> <B>FOR INFORMATION ONLY</B><Br>Search, Quote 
	and index technology developed by eLogic.Historical information supplied by Iverson Financial 
	, news articles contibuted by Reuters, PRNewswire and BusinessWire. Data and information 
	is provided for informational purposes only, and is not intended for trading purposes. Neither eLogic 
	nor any of its data or content providers shall be liable for any errors or delays in the content, 
	or for any actions taken in reliance thereon.</font>

		</td>
	</tr>
</table>


<!-- Begin DoubleClick ad foot -->
<LAYER SRC="http://ad.doubleclick.net/adl/finance.individual.com/PNP_search_results;kw=;tickr=TEVA;!category=fin_comp;mode=display_news;u=;sz=468x60;ord=1209?" visibility=hide onload="moveToAbsolute(banner1.pageX, banner1.pageY); clip.height=80; clip.width=468; visibility='show';"></LAYER>
<!-- End DoubleClick ad foot -->

<!-- Begin DoubleClick ad foot -->
<LAYER SRC="http://ad.doubleclick.net/adl/finance.individual.com/PNP_search_results_column;kw=;tickr=TEVA;!category=fin_comp;mode=display_news;u=;sz=150X500;ord=31209?" visibility=hide onload="moveToAbsolute(column1.pageX, column1.pageY); clip.height=500; clip.width=150; visibility='show';"></LAYER>
<!-- End DoubleClick ad foot -->


<!-- eLogic.com publishing systems 8/18/00 Time-3:48:55 AM -->



</BODY>
</HTML>